MBI Provides Shareholder Update
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 02/03/15 -- Med BioGene Inc. ("MBI" or the "Company") (TSX VENTURE: MBI) is pleased to provide the following report of the Company''s activities over the last four months for the benefit of shareholders and the investment community. Since our last letter to Shareholders on October 1st, 2014, there have been a number of developments of which shareholders should be made aware.
Summary:
After the September 17th, 2014 conference call with Precision Therapeutics Inc. ("PTI") to discuss its updated presentation summarizing its development plans for 2015, MBI was contacted by PTI''s management and informed that significant organizational changes were planned. These included the intention to rename PTI as Helomics®, the appointment of Dr. Neil Campbell as the new CEO, and the adoption of a very focused strategy designed to accelerate the commercialization of their range of prognostic genome-based products.
In early November, the renaming as Helomics® was formally announced, and Dr. Campbell became CEO. Soon after this, one of our Directors travelled to Pittsburgh and met with the Helomics® team. In the subsequent three months the Company''s Directors have met with Helomics® on a number of occasions, both in Pittsburgh and in San Francisco, and have also had a number of conversations to discuss matters of mutual interest. At the end of January, Helomics® and MBI had further discussions covering the following topics:
Commercialization of GeneFX Lung
Other matters which may be of interest to MBI shareholders include the following:
Conclusions
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Certain information in this press release contains forward-looking information and statements ("forward-looking information") of MBI under applicable Canadian and United States legislation. Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but is not limited to, that with respect to the timing, completion and/or results of clinical trials or studies, the timing for commercialization of any products, future profits, future product revenues, future shareholder value, future operations and plans, the completion and use of proceeds from transactions or financings and the prospects for negotiating partnerships or collaborations and their timing. This forward-looking information is only a prediction based upon MBI''s current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and is based upon uncertain assumptions that could cause MBI''s actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speak only as of the date of this press release. MBI''s forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking information herein is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any such forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law. Certain information included in this press release in respect of Helomics® and its scientific, clinical and/ or commercialization efforts and expectations have been provided to MBI by Helomics®. MBI may not have been able to confirm the accuracy of such information and you should not place undue reliance on any such information, including any information regarding Helomics® that may constitute forward-looking information. A redacted copy of the commercialization agreement between MBI and Helomics® may be found at . Each trademark, trade name or service mark of any entity appearing in this press release belongs to its holder.
Contacts:
Med BioGene Inc.
Iain Weir-Jones
Chief Executive Officer
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.02.2015 - 17:56 Uhr
Sprache: Deutsch
News-ID 1334640
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MBI Provides Shareholder Update
"
steht unter der journalistisch-redaktionellen Verantwortung von
Med BioGene Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
